|
|
|
|
| LEADER |
01000cam a22002652 4500 |
| 001 |
1773204467 |
| 003 |
DE-627 |
| 005 |
20230125174756.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
211011s2016 xx |||||o 00| ||eng c |
| 035 |
|
|
|a (DE-627)1773204467
|
| 035 |
|
|
|a (DE-599)KEP068691149
|
| 035 |
|
|
|a (NCBI)9917002733406676
|
| 035 |
|
|
|a (EBP)068691149
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rda
|
| 041 |
|
|
|a eng
|
| 245 |
1 |
0 |
|a Mepolizumab (Nucala)
|
| 264 |
|
1 |
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2016 Nov
|
| 300 |
|
|
|a 1 online resource
|b illlustration.
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 490 |
0 |
|
|a Common drug review
|
| 500 |
|
|
|a Includes bibliographical references. - Description based on online resource; title from Bookshelf title screen (viewed February 19, 2017)
|
| 520 |
|
|
|a The objective of this review is to evaluate the beneficial and harmful effects of mepolizumab 100 mg subcutaneous (SC) for the maintenance treatment of adult patients with severe eosinophilic asthma (SEA) whose symptoms are inadequately controlled with high-dose inhaled corticosteroid(s)(ICS) and one or more additional asthma controllers.
|
| 650 |
|
2 |
|a Asthma
|x drug therapy
|0 https://id.nlm.nih.gov/mesh/D001249Q000188
|
| 650 |
|
2 |
|a Eosinophils
|x drug effects
|0 https://id.nlm.nih.gov/mesh/D004804Q000187
|
| 650 |
|
2 |
|a Adrenergic beta-2 Receptor Agonists
|x therapeutic use
|0 https://id.nlm.nih.gov/mesh/D058666Q000627
|
| 650 |
|
2 |
|a Adrenergic beta-2 Receptor Agonists
|x adverse effects
|0 https://id.nlm.nih.gov/mesh/D058666Q000009
|
| 655 |
|
2 |
|a Review
|0 https://id.nlm.nih.gov/mesh/D016454
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health,
|e MitwirkendeR
|4 ctb
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK409875/
|m X:NCBI
|x Verlag
|z teilw. kostenfrei
|
| 912 |
|
|
|a ZDB-193-NCB
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a ISIL_DE-18
|
| 912 |
|
|
|a SYSFLAG_1
|
| 912 |
|
|
|a GBV_KXP
|
| 912 |
|
|
|a GBV_ILN_22_i06404
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a ISIL_DE-7
|
| 912 |
|
|
|a GBV_ILN_74
|
| 912 |
|
|
|a ISIL_DE-354
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a ISIL_DE-25
|
| 912 |
|
|
|a GBV_ILN_2009
|
| 912 |
|
|
|a ISIL_DE-180
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a ISIL_DE-15
|
| 951 |
|
|
|a BO
|
| 980 |
|
|
|2 22
|1 01
|x 0018
|b 3994101018
|h h64 NCBI
|y zi06404
|z 21-10-21
|
| 980 |
|
|
|2 40
|1 01
|x 0007
|b 3994027284
|h OLR-NCB-BOOKSHELF
|y xsn
|z 21-10-21
|
| 980 |
|
|
|2 74
|1 01
|x 0354
|b 3999803886
|c 09
|f E-Bibl
|d EM 0000
|e --%%--
|j --%%--
|y ze
|z 08-11-21
|
| 980 |
|
|
|2 2003
|1 01
|x DE-25
|b 3995695930
|c 00
|f --%%--
|d --%%--
|e --%%--
|j n
|k Elektronischer Volltext - Open Access
|y l01
|z 25-10-21
|
| 980 |
|
|
|2 2009
|1 01
|x DE-180
|b 3987694629
|c 00
|f --%%--
|d --%%--
|e --%%--
|j --%%--
|y l01
|z 11-10-21
|
| 980 |
|
|
|2 2010
|1 01
|x DE-15
|b 3987782781
|c 00
|f --%%--
|d --%%--
|e --%%--
|j n
|k Elektronischer Volltext - Open Access
|y l01
|z 11-10-21
|
| 981 |
|
|
|2 22
|1 01
|x 0018
|r https://www.ncbi.nlm.nih.gov/books/NBK409875/
|
| 981 |
|
|
|2 40
|1 01
|x 0007
|y Volltext, Open Access
|r https://www.ncbi.nlm.nih.gov/books/NBK409875/
|
| 981 |
|
|
|2 74
|1 01
|x 0354
|r https://www.ncbi.nlm.nih.gov/books/NBK409875/
|
| 981 |
|
|
|2 2003
|1 01
|x DE-25
|r https://www.ncbi.nlm.nih.gov/books/NBK409875/
|
| 981 |
|
|
|2 2010
|1 01
|x DE-15
|y Online-Zugriff
|r https://www.ncbi.nlm.nih.gov/books/NBK409875/
|
| 985 |
|
|
|2 22
|1 01
|x 0018
|a h64 ebook
|
| 985 |
|
|
|2 74
|1 01
|x 0354
|a EM 0000
|
| 995 |
|
|
|2 22
|1 01
|x 0018
|a h64 NCBI
|
| 995 |
|
|
|2 22
|1 01
|x 0018
|a h64 freie Ressource
|
| 995 |
|
|
|2 40
|1 01
|x 0007
|a OLR-NCB-BOOKSHELF
|
